Accipio Dxg (discontinued)

MaxQ AI, Ltd.

**In January 2022 MaxQ announced the discontinuation of their imaging AI product portfolio.**
Accipio Dxg aids in triaging by case-level identification of suspected intracranial hemorrhage positive finding or absence of ICH.

Product specifications

Information source: Vendor
Last updated: Jan. 21, 2022

General
Product name	Accipio Dxg (discontinued)
Company	MaxQ AI, Ltd.
Subspeciality	Neuro
Modality	CT
Disease targeted	Intracranial hemorrhage
Key-features	Identification and triage of non-contrast head exams without suspected ICHs.
Suggested use	Before: adapting worklist order
Data characteristics
Population	Stroke and head trauma patients suspicious of intracranial hemorrhage.
Input	Adult non-contrast head CT exam
Input format	DICOM
Output	Triage with notification
Output format	DICOM Secondary Capture
Technology
Integration	Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis	Automatically, right after the image acquisition
Processing time
Certification
CE	Certified, Class IIb , MDD
FDA	No or not yet
Market presence
On market since	12-2020
Distribution channels	GE, Philips, FujiFilm, IBM, Nuance, Blackford
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use, Subscription
Based on	Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers